...
首页> 外文期刊>Clinical Immunology, Endocrine & Metabolic Drugs >Clomiphene Citrate, Metformin or Aromatase Inhibitors for Anovulatory Infertility in Women with Poly cystic Ovary Syndrome (PC OS): A Systematic Review of Meta-analyses and Randomized Controlled Trials
【24h】

Clomiphene Citrate, Metformin or Aromatase Inhibitors for Anovulatory Infertility in Women with Poly cystic Ovary Syndrome (PC OS): A Systematic Review of Meta-analyses and Randomized Controlled Trials

机译:多囊卵巢综合征(PC OS)妇女无排卵性柠檬酸克罗米芬,二甲双胍或芳香化酶抑制剂:荟萃分​​析和随机对照试验的系统评价。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Several drugs are actually used for treating women with polycystic ovary syndrome (PCOS). These included mainly clomiphene citrate (CC), metformin or aromatase inhibitors (AIs). Objectives; To review systematically the literature for meta-analyses and randomized controlled trials (RCTs) in order to clarify evidence based indications for the use of CC, metformin and AIs in the treatment of infertility in anovulatory patients with PCOS. Search Strategy: We searched and reviewed until September 2012 the main databases available. Selection Criteria: Meta-analyses and RCTs. Live-birth rate was considered as primary end-point. Data Collection and Analysis: Authors independently reviewed and extracted the data. Main Results: Fourteen meta-analyses and nine additional RCTs were analyzed showing heterogeneous results for several treatment comparisons. Conclusions: In infertile obese PCOS patients, the CC should be stiE considered the drugs of choice for inducing ovulation. Letrozole, even if is the only AI supported by evidence-based data, is not better than CC in therapy naive patients. In patients with CC resistance, metformin plus CC improves significantly the reproductive outcomes, with particular regard for obese subjects.
机译:背景:几种药物实际上用于治疗患有多囊卵巢综合征(PCOS)的女性。这些主要包括柠檬酸克罗米芬(CC),二甲双胍或芳香酶抑制剂(AIs)。目标;系统地复习有关荟萃分析和随机对照试验(RCT)的文献,以阐明CC,二甲双胍和AI在无排卵性PCOS患者不孕症治疗中基于证据的适应症。搜索策略:我们搜索并审查了直到2012年9月的可用主要数据库。选择标准:荟萃分析和RCT。活产率被认为是主要终点。数据收集和分析:作者独立查看和提取数据。主要结果:对十四项荟萃分析和九项其他RCT进行了分析,结果显示异质性结果用于几种治疗比较。结论:对于不育型肥胖PCOS患者,应考虑将CC作为诱导排卵的首选药物。来曲唑即使是唯一由循证数据支持的AI,在未接受过治疗的患者中也不比CC更好。在患有CC抵抗的患者中,二甲双胍加CC可以显着改善生殖结局,尤其是对于肥胖受试者。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号